- Home
- INHD vs NXTC Comparison
INHD vs NXTC Comparison
Compare INHD & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INHD
- NXTC
- Stock Information
- Founded
- INHD 2019
- NXTC 2015
- Country
- INHD United States
- NXTC United States
- Employees
- INHD N/A
- NXTC N/A
- Industry
- INHD
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- INHD
- NXTC Health Care
- Exchange
- INHD Nasdaq
- NXTC Nasdaq
- Market Cap
- INHD 19.8M
- NXTC 21.6M
- IPO Year
- INHD 2023
- NXTC 2019
- Fundamental
- Price
- INHD $4.63
- NXTC $0.72
- Analyst Decision
- INHD
- NXTC Strong Buy
- Analyst Count
- INHD 0
- NXTC 2
- Target Price
- INHD N/A
- NXTC $4.00
- AVG Volume (30 Days)
- INHD 25.5K
- NXTC 62.2K
- Earning Date
- INHD 02-14-2025
- NXTC 03-20-2025
- Dividend Yield
- INHD N/A
- NXTC N/A
- EPS Growth
- INHD N/A
- NXTC N/A
- EPS
- INHD N/A
- NXTC N/A
- Revenue
- INHD $916,878.00
- NXTC N/A
- Revenue This Year
- INHD N/A
- NXTC N/A
- Revenue Next Year
- INHD N/A
- NXTC N/A
- P/E Ratio
- INHD N/A
- NXTC N/A
- Revenue Growth
- INHD 39.48
- NXTC N/A
- 52 Week Low
- INHD $3.00
- NXTC $0.66
- 52 Week High
- INHD $12.23
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- INHD 47.09
- NXTC 40.34
- Support Level
- INHD $4.47
- NXTC $0.66
- Resistance Level
- INHD $4.72
- NXTC $0.79
- Average True Range (ATR)
- INHD 0.19
- NXTC 0.06
- MACD
- INHD -0.01
- NXTC 0.00
- Stochastic Oscillator
- INHD 29.63
- NXTC 42.21
About INHD Inno Holdings Inc.
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.